81% of Clinical Trial Volunteers Suffer Reactions to CanSino Biologics’ COVID-19 Vaccine

 

  • IN BRIEF
  • The Facts:Multiple clinical trials for COVID-19 vaccines have shown severe reactions within 10 days after taking the vaccine.
  • Reflect On:Should we think twice about taking a rushed vaccine? Is it even necessary given the remarkably low death rate?

What Happened: COVID-19 vaccines have been in production for several months now, and clinical trials have been underway in various countries. One experimental vaccine being developed by CanSino Biologics, Inc. of Tianjin, China, has completed phase 1 of human clinical trials for COVID-19 vaccine (adenovirus type-5 Ad5-nCoV) and involved 108 volunteers, ranging in age from 45–60 years old.

According to researchers conducting the study on the Phase 1 clinical trial for the Ad5-nCoV vaccine:

The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients. Pain was reported in 17 (47%) participants in the low dose group, 20 (56%) participants in the middle dose group, and 21 (58%) participants in the high dose group. The most commonly reported systematic adverse reactions overall were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]). Fever was reported in 15 (42%) participants in the low dose group, 15 (42%) participants in the middle dose group, and 20 (56%) participants in the high dose group. Headache was reported in 14 (39%) participants in the low dose group, 11 (31%) participants in the middle dose group, and 17 (47%) participants in the high dose group. Muscle pain was reported in seven (19%) participants in the low dose group, three (8%) participants in the middle dose group, and eight (22%) participants in the high dose group.

The U.S. Department of Health and Human Services (HHS) describes a Grade 3 adverse event as “severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care” such as “bathing, dressing and undressing, feeding self, using the toilet, taking medications.”

CanSino’s Ad5-n-CoV vaccine uses a chimpanzee adenovirus vector that uses the HEK293 cell lines derived from the tissue of an aborted fetus. The HEK293 human fetal cell line, which was designed, developed and is licensed by Canada’s National Research Council (NRC), is also being used to produce the AZD1222 COVID-19 vaccine developed by the University of Oxford’s Jenner Institute.

 Why It Matters: COVID-19 vaccines are being rushed to market, and vaccines that are rushed to market never ave a good safety record. Given that even Moderna’s COVID vaccine also showed negative reactions, people should think twice about opting in for the vaccine, especially given COVID-19 is continuing to prove it is not as dangerous or life-threatening as mainstream media has been making it sound.

While the introduction of a vaccine will mean huge dollars for pharmaceutical companies, like the seasonal flu vaccine, it seems unnecessary and potentially can cause more harm than the good it could do. Vaccines for illnesses similar to COVID-19 often don’t protect high percentages of takers from the illness it attempts to prevent.

The Takeaway: There has been a great deal of discussion regarding the introduction of a vaccine, ID card and mandating medicine in one final push towards deep authoritarian control by members of the societal and financial elite. This includes people like Bill Gates. Is this the big push for total control that has long been talked about and built up to ever since 9/11? Is the promise of contact tracing and ID cards “to keep the world safe” really what this is about? Or does the track record on measures like this prove that it’s never about ‘the virus’ and more so about the control that comes as a result of the measures that stick around long after the virus is gone?

https://www.collective-evolution.com/2020/07/11/81-of-clinical-trial-volunteers-suffer-reactions-to-cansino-biologics-covid-19-vaccine/

Print Friendly, PDF & Email
Facebooktwitterredditpinterestlinkedinmail

Leave a Reply

You must be logged in to post a comment.